Top CDMO Regions in 2026: US vs India vs Europe

Where you manufacture is now a strategic decision, not just a cost one. Geopolitical risk, tariffs, and regulatory familiarity weigh as heavily as price. Here is how the three major contract manufacturing regions compare for pharma sourcing teams in 2026.

United States

• Strengths: Regulatory proximity to the FDA, strong IP protection, fast communication for US sponsors, and growing domestic-manufacturing incentives.
• Trade-offs: Higher cost base; capacity for some modalities is constrained.
• Best for: Commercial supply where regulatory familiarity and supply-chain security justify the premium.

Browse manufacturers and suppliers in the United States.

India

• Strengths: Deep API and generics expertise, large qualified capacity, and competitive cost. India has shifted from pure generics toward higher-value innovative manufacturing.
• Trade-offs: Longer lead times for some markets; diligence on quality systems and FDA inspection history is essential.
• Best for: Cost-efficient API supply and scale, with rigorous FDA compliance screening.

Browse companies in India.

Europe

• Strengths: Strong biologics and sterile manufacturing capability (notably Ireland, Switzerland, and Germany), high quality-system maturity, and EMA proximity.
• Trade-offs: Premium pricing; capacity for in-demand modalities books out early.
• Best for: Biologics, sterile injectables, and EU-market supply.

Browse manufacturers in Germany, Switzerland, and Ireland.

How to choose between them

Priority	Favors
Lowest API cost at scale	India
Regulatory proximity (US market)	United States
Biologics / sterile fill-finish	Europe
Supply-chain security	US or dual-region

Most resilient supply strategies don't pick one region — they dual-source across regions to balance cost against risk. Whichever region you favor, screen candidates for FDA compliance history before committing. Start building a shortlist in the supplier directory or read our CDMO selection checklist.